María-Victoria Mateos, MD, PhD, consultant physician, Hematology Department, associate professor of medicine, University of Salamanca, discusses long-term overall survival data from the phase 3 CARTITUDE-4 trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel; Carvykti) in lenalidomide (Revlimid)-refractory multiple myeloma.